About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 40924 record(s)
Req # A-2024-000123
In respect of the second, newest Abbreviated New Drug Submission (ANDS) for semaglutide (the Second Semaglutide ANDS), please provide a copy of the most recent Certified Product Information Document (CPID) submitted by the sponsor.Organization: Health Canada
August 2024
Req # A-2024-000125
In respect of the second, newest Abbreviated New Drug Submission (ANDS) for semaglutide (the Second Semaglutide ANDS), please provide a copy of any Screening Acceptance Letter sent by Health Canada to the sponsor of the Second Semaglutide ANDS.Organization: Health Canada
August 2024
Req # A-2024-000149
All records and documentation for health product recall number RA-72773. Records confirming the basis for the Recall, as well as any representations or communications. Date range January 1, 2015 to April 17, 2020.Organization: Health Canada
August 2024
Req # A-2024-000157
For each communication number referenced below, provide all material associated with the meetings or activities listed in the Registry of Lobbyists for Pfizer: 15283-470669, 15283-491740, 15283-495755, 15283-495757, 15283-498868, 15283-498870, 15283…Organization: Health Canada
August 2024
Req # A-2024-000220
Notice(s) of Violation issued to individual(s) or organization(s) under the Cannabis Act or its Regulations, as referenced on the following webpage: Administrative monetary penalties under the Cannabis Act - Canada.ca.Organization: Health Canada
August 2024
Req # A-2024-000244
All communications to and from Breast Cancer Canada that are held by Health Canada from 2024-03-12 to 2024-05-30.Organization: Health Canada
August 2024
Req # A-2024-000251
The draft product monograph included in the initial filing of the Abbreviated New Drug Submission (ANDS) for Aripiprazole from Jamp Pharma Corporation accepted into review in April 2024 and subsequently, included in the list of Generic submissions…Organization: Health Canada
August 2024
Req # A-2024-000252
The cover letter which accompanied the initial filing of the Abbreviated New Drug Submission (ANDS) for Aripiprazole which was accepted into review in April 2024 and subsequently, included in the list of Generic submissions under review dated 2024-…Organization: Health Canada
August 2024
Req # A-2024-000258
The cover letter which accompanied the initial filing of the Abbreviated New Drug Submission (ANDS) for Tolvaptan which was accepted into review in November 2023 and, is included in the list of Generic submissions under review dated 2024-05-23 and…Organization: Health Canada
August 2024
Req # A-2024-000265
The most recent draft version and any existing feedback pertaining to the performance measurement evaluation for ethylene oxide, mentioned at this Uniform Resource Locator (URL) for greater clarity: https://www.canada.ca/en/health-canada/services/…Organization: Health Canada
August 2024